Is Mineralys Therapeutics, Inc. (MLYS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 9.4% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 9.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 96.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 9.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 96.3% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -36.9% | |
| Return on Assets (ROA) | -24.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$142M |
| Free Cash Flow | -$142M |
| Current Ratio | 43.8 |
| Total Assets | $662M |
Price & Trading
| Last Close | $23.61 |
| 50-Day MA | $28.60 |
| 200-Day MA | $29.36 |
| Avg Volume | 1.2M |
| Beta | 0.6 |
|
52-Week Range
$10.44
| |
About Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Mineralys Therapeutics, Inc. (MLYS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Mineralys Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Mineralys Therapeutics, Inc.'s debt ratio?
Mineralys Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Mineralys Therapeutics, Inc.'s key financial metrics?
Mineralys Therapeutics, Inc. has a market capitalization of $2.0B. Return on equity stands at -36.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.